Study investigates factors associated with survival in glioma with leptomeningeal metastases

  • A study of 226 glioma patients with leptomeningeal metastases (LM) aimed to identify patient and treatment variables associated with survival outcomes.
  • The median overall survival (OS) was 17.0 months, and was significantly shorter in people with initial versus recurrent LM (12.2 vs 20.6 months). Use of chemotherapy or antiangiogenic therapy was significantly associated with longer OS in the overall study population, whereas male sex was significantly associated with shorter OS.
  • When patients were categorized according to LM recurrence, predictors of longer OS in those with initial LM included higher Karnofsky performance status, chemotherapy, and antiangiogenic therapy, and predictors of longer OS in those with recurrent LM were chemotherapy and longer interval between initial glioma and LM diagnoses. Male sex was a predictor of shorter OS in both groups.